COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
07/04/2026
Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a) SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical [...]
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
07/04/2026
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
07/04/2026
New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia ™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner- [...]
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
07/04/2026
RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has [...]
Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
07/04/2026
BERKELEY, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the company will present new preclinical data highlighting the [...]
Solid Biosciences to Participate at Upcoming Investor Conferences
07/04/2026
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
07/04/2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistance foundations [...]
GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment
07/04/2026
IRVINE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, and researchers from the University of [...]
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
07/04/2026
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcare [...]
electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD
07/04/2026
ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a [...]
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
07/04/2026
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial [...]
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
07/04/2026
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701 monotherapy data accepted [...]
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
07/04/2026
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
07/04/2026
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
07/04/2026
Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London Clinic, [...]
NTG Nordic Transport Group A/S - Q1 2026 Conference Call
07/04/2026
NTG Nordic Transport Group A/S – Q1 2026 Conference Call We expect to release the Q1 2026 interim results of NTG Nordic Transport Group on the evening of May 5, 2026. A webcast and conference call will be held in the [...]
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
07/04/2026
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026 The trial has already yielded encouraging one- and two-year data including a 75% Objective [...]
Route 92 Medical Announces $50 Million Growth Financing
07/04/2026
New investor Sectoral Asset Management joins growth financing round to support acceleration of commercial growth WEST JORDAN, Utah, April 07, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical [...]
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
07/04/2026
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; [...]

Pages